Topical drug delivery for AMD

Press/Media: Press / Media


Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.

Period23 Jul 2018

Media coverage


Media coverage

  • TitleResearchers Are One Step Closer to Developing Eye Drops to Treat Age-related Macular Degeneration (AMD)
    Degree of recognitionInternational
    Media name/outletMarketplace (web)
    Media typeWeb
    Country/TerritoryUnited Kingdom
    DescriptionAMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.

    AMD is currently treated by disagreeable injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham's Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drugs as eye drops.
    PersonsFelicity De Cogan